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Abstract
Background: TBM (Tuberculous meningitis) is severe form of tuberculosis causing death of one third of the
affected individuals or leaving two-third of the survivors disabled. MMP-9 (Matrix metalloproteinase-9) is produced
by the central nervous system in a variety of inflammatory conditions and has a role in the breakdown of
extracellular matrix and blood–brain barrier.
Methods: In this study, the levels of MMP-9 and its inhibitor, TIMP-1 (tissue inhibitor of metalloproteinases-1), were
screened using zymography and reverse zymography in cerebrospinal fluid and serum of tuberculous meningitis
patients at different stages of the disease. Further, role of MMP-9 as therapeutic target was studied in C6 glioma
cells infected with Mycobacterium tuberculosis H37Rv. Cells were treated with dexamethasone or SB-3CT (specific
inhibitor of MMP-9) in combination with conventional antitubercular drugs.
Results: MMP-9 levels in patients were increased as the disease progressed to advanced stages. The infection led
to increased MMP-9 levels in C6 glioma cells and specific inhibition of MMP-9 by SB-3CT augmented bacillary
clearance when used along with antitubercular drugs.
Conclusion: MMP-9 plays a prominent role in progression of tuberculous meningitis from initial to advanced
stages. Increased levels of MMP-9 during advancement of the disease leads to degeneration of nervous tissue and
blood brain barrier disruption. Hence, MMP-9 can be considered as a therapeutic target for efficient management
of TBM and can be explored to inhibit further progression of the disease if used at an early stage.
Keywords: Antitubercular drugs, Inflammation, Mycobacterium tuberculosis, Matrixmetalloproteinase-9, SB-3CT,
Tissue inhibitor of metalloproteinase-1, Tuberculous meningitis
Background
Tuberculous meningitis is the highest mortality causing
form of tuberculosis, one third of the patients die and
more than half of survivors are left disabled after con-
tracting the disease [1, 2]. Severe clinical manifestations
of tuberculous meningitis occur due to robust inflamma-
tory response generated in the brain against pathogenic
bacilli [3]. During this process, microglial cells are acti-
vated to secrete proteases which have ability to degrade
extracellular matrix and cause tissue destruction [4, 5].
Among these proteases, MMPs seem to have prominent
role in tissue destruction. MMPs are endopeptidases
which degrade all the components of the extracellular
matrix and thus have potential to disrupt blood brain
barrier and cause CNS damage [5]. Tuberculosis infec-
tion elicits the production of MMP-9 by direct inter-
action between cell wall components of bacilli, human
monocytes and macrophages.[6] The higher increase of
MMP-9 in pleural effusions of tuberculous meningitis
patients than in patients with malignant pleural disease
also signifies the role of MMP-9 in tuberculous infec-
tions and vice versa [7]. Besides, the synergistic effects of
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MMP-9 and Mycobacteria on each other, specific MMP-
9 substrates type IV collagen and laminin, constitute es-
sential structural components of the blood brain barrier
reflecting its importance in tissue damage. The possibil-
ity of using MMP-9 inhibition as therapeutic target can
be considered for preventing progression of disease to
advanced stages and control disabilities. Currently corti-
costeroids like dexamethasone or prednisolone are usu-
ally given along with conventional antitubercular drugs
to combat the inflammatory tissue degradation which
nonspecifically inhibits MMP 9 as well [8, 9]. Specific in-
hibitor of MMP-9, SB-3CT has come forth with desir-
able properties of crossing blood brain barrier and
therapeutic effects for treating neurological diseases due
to inflammation [10]. This inhibitor has been studied for
ischemia of immature brain and found to work effi-
ciently; showing its utility in pediatric cases [11]. In this
study, role of MMP-9 has been evaluated in progression
of TBM. The levels of MMP-9 at different stage of the
disease were compared to evaluate if any correlation ex-
ists between the worsening prognosis and MMP-9 levels.
Though the inflammatory tissue destruction amplifies as
the disease progresses from stage I to stage III, no study
is available on the exact contribution of these MMPs in
advancement of the disease. Effect of specific inhibition
of MMP-9 on clearing the bacterial burden were further
evaluated in C6 glioma cells infected with Mycobacter-
ium tuberculosis H37Rv.
Methods: availability of data and material section
Ethical considerations
The plan of work was approved by Institutional Ethics
Committee (IEC) of Postgraduate Institute of Medical
education and Research, Chandigarh, and sample collec-
tion was done according to the ethical guidelines. CSF
and blood samples were used after written consent from
the patients or their attendants in case of unconscious
or confused patients. The written consent was recorded
in patient proforma approved by Institutional Ethical
Committee.
Chemicals and consumables
Isoniazid, Rifampicin, Pyrazinamide, Dexamethasone,
MMP-9 standard, MMP-9 inhibitor (SB-3CT) and gel-
atin were obtained from Sigma (St. Louis USA). OADC
(Oleic albumin dextrose catalase) enrichment and 7H11
agar were obtained from Difco-Becton-Dickinson (USA),
FBS (fetal bovine serum) and MEM (minimum essential
medium) were obtained from Invitrogen Corporation
(Gibco), New York, USA. Acrylamide, bisacrylamide,
ammonium persulphate and other reagents used were of
molecular grade. Ultrapure water was used throughout
the study.
Mycobacterial culture and cell lines
Mycobacterium tuberculosis H37Rv (NCTC7416) was
originally obtained from National Collection of Type
Culture (NCTC) London, UK. Bacteria were grown in
sterile Sautons’s medium and maintained in sterile
lowenstein-jensen medium. Cultures were grown under
shaking conditions at 180 rpm, 37 °C.
Cell lines
C6 glioma and HT1080 cell lines were purchased from
National Centre for Cell Science, Pune. C6 glioma cells
were grown in MEM supplemented with 10% FBS,
HT1080 cells were also grown in MEM supplemented
with 10 mM sodium pyruvate and 10% FBS, grown at
37 °C in a humidified incubator under 5% C02 and 95%
air. Cells were maintained as frozen aliquots of 10%
DMSO in FBS at −80 °C. Conditioned media containing
gelatinases was obtained by growing HT-1080 cells ini-
tially in MEM supplemented with 10% FBS and then in
serum-free MEM for 24 h.
Study design, site and population
Study subjects included patients with TBM attending
Neurology, Emergency or Internal medicine departments
at PGIMER, Chandigarh, India. Patients above 12 years
of age and of either sex were included in the study.
Patients infected with HIV or suffering from any other
infectious disease in addition to TBM were excluded
from the study. The plan of work was approved by Insti-
tutional Ethics Committee of Postgraduate Institute of
Medical Education and Research, Chandigarh and sam-
pling was carried out according to the ethical guidelines.
CSF and blood samples were used after written consent
from the patients or their attendants in case of uncon-
scious or confused patients. Samples were taken during
treatment of patients. The written consent was recorded
in patient proforma, which was approved by Institutional
Ethical Committee. Performa was used to collect the
demographic and clinical information, including age,
sex, HIV status, duration, regimen, tests and examina-
tions of previous treatment, etc. Ninety-one patients
with clinical symptoms of TBM and 16 control subjects
were included in the study. The selection of patients was
based on the criteria defined by Mahadevan et al. [12]
i.e. fever over a period of week, high protein sugar ratio
in cerebrospinal fluid, imaging studies of head showing
exudates, hydrocephalus, infarcts, cranial nerve palsies,
response to antitubercular drug therapy and final con-
firmation of tuberculous meningitis by the clinician at-
tending the patient. According to the guidelines of
British Medical Research Council (MRC), the patients
were categorized into three stages I, II and III as per the
symptoms shown by the patients. Stage I included con-
scious and rational patients with no signs of focal or
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neurological deficits or neck stiffness, Stage II patients
were conscious but confused had focal signs such as cra-
nial nerve palsies or hemiparesis. Patients in stage III
were comatose or delirious with or without dense neuro-
logical deficit. Controls subjects were those having non
inflammatory disease. CSF and blood samples were
obtained from patients in different stages of TBM (10
patients with stage I, 42 with stage II, 39 with stage III)
and 16 control subjects. CSF sample was obtained by
lumbar puncture during their hospitalization and blood
sample (5 ml) was drawn in sterile tube and processed
for serum separation. CSF and serum samples were ster-
ile filtered and immediately frozen at −80 °C till assayed
for MMP-9 and TIMP-1 levels.
Gelatin-substrate zymography
MMP-9 levels in CSF and serum were monitored by gel-
atin zymography using 8% polyacrylamide gels contain-
ing 0.3% SDS and gelatin (1 mg/ml) [13]. Undiluted CSF
and serum (1:100 dilutions) was mixed with zymography
buffer [50 mM Tris–HCl, 10% glycerol, 2% SDS and
0.01%bromophenol blue]. Samples were loaded and run
at 20 mA for 20 min and then at 30 mA for 60 min.
Equal amount of each sample was used for analysis. Au-
thentic MMP-9 standard was also run as control. Gels
were agitated in 2.5% TritonX-100 and washed in
50 mM Tris–HCl buffer, pH 7.5 containing 200 mM
NaCl. Thereafter, gels were incubated overnight at 37 °C
in renaturing buffer (50 mM Tris–HCl buffer, pH 7.5
containing 200 mM NaCl, 5 mM CaCl2, 0.02% (w/v)
brij-35, and 0.01% sodium azide. Finally, gels were
stained with Comassie G blue and or silver stained to
obtain the bands. Intensities of gelatinolytic bands corre-
sponding to MMP-9 were measured by software analysis
[13, 14] The densitometric intensities of known concen-
trations of MMP-9 standard were plotted to obtain
standard curve from which MMP-9 concentrations in
patient samples was determined.
Reverse zymography
TIMP-1 in CSF and serum samples was analyzed by re-
verse zymography. 15% polyacrylamide gels with gelatin
and gelatinases copolymerized into the matrix were pre-
pared. Gelatinases were obtained from serum free media
of HT1080 fibrosarcoma cell line. Samples were mixed
with zymography buffer and run for electrophoresis.
Gels were agitated in 2.5% TritonX-100, washed in
50 mM Tris–HCl buffer, and incubated overnight in re-
naturation buffer for action of gelatin and gelatinases.
During the activation step, gelatinases present in gel
digest the gelatin but only in areas where TIMPs are
absent. Upon staining, the levels were monitored as
blue bands of undigested gelatin on a clear gelatinolytic
background [15].
Effect of MMP-9 inhibition on C6 glioma cells infected
with Mycobacterium tuberculosis
C6 glioma cells were plated in 24 well plates and infected
with Mycobacterium tuberculosis H37RV in ratio of 10 bacilli
per cell. After 90 min., the cells were washed extensively to
remove extracellular bacteria. Cells were divided into seven
groups Group I: uninfected cells, Group II: cells infected
with Mycobacterium tuberculosis H37RV, Group III: infected
cells treated with dexamethasone, Group IV: infected cells
treated with MMP-9 inhibitor (SB- 3CT), Group V: infected
cells treated with antitubercular drugs, Group VI: infected
cells treated with antitubercular drugs along with dexa-
methasone, Group VII: infected cells treated with antituber-
cular drugs along with SB-3CT. Concentration of drugs,
dexamethasone and SB-3CT used was as described
[16–18]. After 5 days of treatment, cells were lysed with
0.1% SDS. Mixture of extra cellular media and cell lysate
was processed for CFU enumeration and MMP-9 analysis.
Statistical analysis
Comparison of MMP-9 levels amongst patients in differ-
ent stages of TBM was performed using Kruskal-Wallis
test. If the overall test was significant (p < 0.05) the
Mann–Whitney test was applied to compare control
subjects with stage I, II, III patients; stage I patients with
stage II, III patients and stage II patients with stage III
patients. All the comparisons were based on mean rank.
Results
Levels of MMP-9 and TIMP-1 in CSF of patients with
advanced stages of TBM
TBM patients selected for the study were grouped into
stage I, II and III as per details given in Table 1. The
amount of MMP-9 in CSF samples was quantified by
comparing their densitomertic values with those of known
concentration of MMP-9 standard. CSF zymography re-
vealed that MMP-9 levels increased with advanced stages
of TBM (Fig. 1a). MMP-9 levels were 0.62 ± 0.40 ng/ml
for controls, 9.0 ± 0.87 ng/ml for stage I, 12.0 ± 1.34 ng/ml
for stage II and 16.86 ± 2.7 ng/ml for stage III tuberculous
meningitis patients (Fig. 1b and c). MMP-9 levels showed
significant increase in samples of stage III patients as com-
pared to stage I and stage II. TIMP-1 was detectable in
Table 1 Demography data of the subjects included in the
study Patients in advanced stages of the disease showed higher











Stage 1 10 36.75±14.1 6:4 121.7±21.5 32.3±6.5
Stage 11 42 34.66±15.5 24:18 135±44.5 31.8±16.3
Stage III 39 53.6±10.5 23:16 245±89.2 25.72±7.9
Control 16 35.93±8.3 10:6 21.2±6.5 63.88±11.3
Majeed et al. BMC Infectious Diseases  (2016) 16:722 Page 3 of 7
stage I TBM patients only. Out of 10 stage I patients, it
was detected in only 3 patients. However, TIMP-1 was de-
tected in all control samples but no sample from stage II
or III patients showed the presence of TIMP-1 (Fig. 2).
Levels of MMP-9 and TIMP-1 in serum samples of patients
with advanced stages of TBM
Increase in MMP-9 levels with advancement of the dis-
ease was observed in serum samples hence confirming
the results obtained with CSF (Fig. 3a). Densitometric
analysis revealed MMP-9 levels of 5.67 ± 2.45 ng/ml for
controls, 830.66 ± 83.07 ng/ml for stage I, 1202.55 ±
136.81 ng/ml for stage II and 1679 ± 277.4 ng/ml for
stage III TBM patients (Fig. 3b). TIMP-1 was not de-
tected in serum sample of any subject.
Evaluation of MMP-9 as therapeutic target using SB-3CT
(MMP-9 inhibitor) and dexamethasone in C6 glioma cells
infected with Mycobacterium tuberculosis H37Rv
Levels of MMP-9 were increased in Mycobacterium
tuberculosis infected C6 cells as compared to the
uninfected cells (Fig. 4a). Ex vivo study can mimic the in
vivo model of Mycobacterium tuberculosis infection where
MMP-9 levels are known to be elevated due to infection.
After confirming the elevation of MMP-9 levels in in-
fected cells, the effect of MMP-9 inhibitor (SB-3CT) and
dexamethasone was monitored in the infected C6 glioma
cells. Levels of MMP-9 were reduced to greater extent
after treatment with either SB-3CT or dexamethasone
(Fig. 4b). Levels of MMP-9 remained unaffected when
treated with antitubercular drugs alone (Fig. 4c.) and were
markedly reduced when drugs were given along with
dexamethasone or SB-3CT, (Fig. 4d). Cells treated with
only SB-3CT or dexamethasone did not show decrease in
CFUs. Interestingly, cells when treated with antitubercular
drugs along with dexamethasone or SB-3CT, showed al-
most undetectable CFUs after 5 days of treatment (Fig. 5).
Discussion
In this study, MMP-9 in CSF as well as serum was in-
creased with progression of disease from stage I to III.
Though increased levels of MMP-9 in TBM has been
Fig. 2 Representative reverse zymogram of TIMP-1 in CSF: Lanes A: stage II; Lanes B, C: stage I; Lane D, stageIII; Lanes E, F: control subjects. Equal
amount of sample was loaded in each lane
Fig. 1 a Representative zymograms showing MMP-9 in CSF: Lane A: control, Lane B: Stage I, Lane C: authentic MMP-9, Lanes D, E: stage III; Lanes F,
G, H: stage II. Equal amount of sample was loaded in each lane (b) Zymogram of known concentrations of standard MMP-9 (c) Box plot showing
MMP-9 levels in CSF of patients in different stages of tuberculous meningitis***p < 0.001 compared to control, ### p < 0.001 compared to stage I and
control, ^^^ p < 0.001 compared to stage II
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reported earlier [13, 19] this study compared the con-
comitant increase in MMP-9 levels with progression of
the disease from earlier to its advanced stages. It was
found that MMP-9 levels were significantly increased as
disease progressed from stage I to II and significant in-
crease was seen as the disease progressed to stage III.
Other low MW gelatinase was also detected which is
predicted to be MMP-2 based on its position on the gel.
The concomitant increase of this gelatinase was also
found with the advancement of the disease but incre-
ment in MMP-9 levels was significantly higher (Fig. 6a
and b). Association of MMP-9 has been observed in nec-
rotic meningeal vessels in TBM. CSF concentrations of
MMP-9 has been correlated with involvement of brain
ischaemia in TBM [20]. MMP-9 levels could not be de-
tected in control samples while the low MW gelatinase
was detected in these samples demonstrating that it is
constitutively expressed. TIMP-1 levels in CSF samples
were decreased with advancement of the disease and
were undetectable in serum samples. Thus overall ratio
of MMP-9/TIMP-1 was found to be increased leading to
matrix degrading phenotype. Studies have found gener-
ation of matrix-degrading phenotype in tuberculosis and
implicate MMP-9 as key mediator in tuberculosis path-
ology [21]. Other studies have reported uncontrolled rise
of MMP-9 in CNS TB due to insignificant levels of
Fig. 3 Representative zymogram of MMP-9 in serum samples of tuberculous meningitis patients. a Lanes A, B, C: stage I; Lane D: control
subject; Lanes H, I, J: stage II. b Box plot showing MMP-9 levels in serum of patients in different stages of TBM ***p < 0.001 compared to control,
### p < 0.001 compared to stage I and control, ^^^ p < 0.001 compared to stage II
Fig. 4 Zymograms of MMP-9 levels in C6 cells (a) Group I: uninfected and Group II: infected cells (b) Group III: dexamethasone treated and Group IV:
SB-3CT treated cells (c) Group V:treated with antitubercular drugs only (d) Group VI: treatment with antitubercular drugs along with dexamethasone
and Group VII: treatment with antitubercular drugs along with SB-3CT (e) Graphical representation of Densitometric units corresponding to MMP-9
bands in different treatment groups of C6 Glioma Cells
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TIMP-1 in comparison to MMP-9 which results in
matrix degrading phenotype [22]. Role of Mycobacter-
ium tuberculosis infections in elevating MMP-9 levels
has also been documented [23]. Thus TBM seems to
have dual relation with MMP-9. MMP-9 is involved in
inflammatory response to disease and on the other hand
Mycobacterium tuberculosis is involved in increasing
MMP-9 levels. The data supporting the inflammatory as
well as pathological role of MMP-9 in tuberculosis re-
veals the possibility of its prominent therapeutic role.
This pilot study demonstrates the apparent role of
MMP-9 in TBM pathology. Further, Mycobacterium
tuberculosis infection enhanced levels of MMP-9 in C6
glioma cells as explained in earlier studies [24] wherein,
conditioned media from Mycobacterium tuberculosis in-
fected monocytes induced MMP-9 secretion from astro-
cytes. MMP-9 inhibitor SB-3CT and dexamethasone was
used to inhibit Mycobacterium tuberculosis induced
MMP-9 in C6 glioma cells. MMP-9 levels were de-
creased in cells treated with SB-3CT or dexamethasone.
These results are in agreement with earlier studies [25].
Levels of MMP-9 were not apparently affected with anti-
tubercular drugs only indicating that antitubercular
drugs are not involved in reducing inflammation in tu-
berculous meningitis patients which explains the life-
long neurological defects even after bacillary clearance.
When drugs were used along with SB-3CT or dexa-
methasone, the MMP-9 levels were decreased to almost
undetectable levels. CFU counts were significantly de-
creased upon treatment with antitubercular drugs. Bacil-
lary counts were further decreased when SB-3CT or
dexamethasone was used along with antitubercular
drugs. No report about combined effects of antitubercu-
lar drugs with SB-3CT is available in the literature.
MMP-9 seems to be a promising molecule to resolve the
destructive outcome of TBM; however, further studies
are required to assign therapeutic significance to MMP-
9 inhibition for better management of TBM.
Conclusions
The present work suggested important role of MMP-9
in tissue destruction during TBM and its progression to
the advanced stages. Specific inhibition of MMP-9 can
be beneficial approach to overcome the limitations of
corticosteroids with equivalent benefits for treatment of
the disease.
Fig. 5 Log10 CFUs of Mycobacterium tuberculosis H37Rv infected C6
glioma cells after 5 days of treatment. Group I: uninfected cells,
Group II: Untreated C6 cells infected with Mycobacterium tuberculosis
H37Rv,Group III: Infected C6 cells treated with Dexamethasone, Group
IV: Infected C6 cells treated with SB-3CT, Group V: Infected C6 cells
treated with antitubercular drugs (Isoniazid + Rifampicin + Pyrazinamide)
Group VI: Infected cells treated with antitubercular drugs along with
dexamethasone, Group VII: Infected cells treated with antitubercular
drugs along with SB-3CT. Values are mean ± SD of cells processed in
triplicate. *** p < 0.001, respect to Group II
Fig. 6 a Representative zymograms showing Low MW gelatinase in different stages of TBM. b Box plot showing comparison of densitometric
values and low MW gelatinase in samples of control subjects and TBM patients
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